Frazier Life Sciences Public Fund, L.P. - 06 Aug 2026 SCHEDULE 13D Report for Attovia Therapeutics, Inc. Common Stock, $0.0001 par value per share

Filing manager
Frazier Life Sciences Public Fund, L.P.
Reporting owner
Frazier Life Sciences XI, L.P.
Security
Attovia Therapeutics, Inc. Common Stock, $0.0001 par value per share
Beneficially owned shares
6,154,213 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D

Active or control-oriented beneficial ownership filing.

Ownership

14%

Beneficial ownership of this reported class.

Shares

6,154,213 shares

Shares beneficially owned as disclosed.

Event date

06 Aug 2026

Date tied to the ownership event or amendment.

Accepted by SEC

11 Aug 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
14%
Subject security Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
45,586,763 shares
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
SCHEDULE 13D
Accepted by SEC
11 Aug 2026, 17:08:27 UTC
Event date
06 Aug 2026
Source filing
View source filing

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 14% ownership in Attovia Therapeutics, Inc. Common Stock, $0.0001 par value per share on 06 Aug 2026.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13D for Attovia Therapeutics, Inc. Common Stock, $0.0001 par value per share.
  • Disclosed ownership: 14%.
  • Date of event: 06 Aug 2026.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 11 Aug 2026, 17:08.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (9)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 1.7% 760,327 0 760,327 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. 0001863769
FHMLSP, L.P. 1.7% 760,327 0 760,327 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. 0001879466
FHMLSP, L.L.C. 1.7% 760,327 0 760,327 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C. 0001879465
Frazier Life Sciences XI, L.P. 14% 6,154,213 0 6,154,213 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. 0001911592
FHMLS XI, L.P. 14% 6,154,213 0 6,154,213 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. 0001911580
FHMLS XI, L.L.C. 14% 6,154,213 0 6,154,213 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C. 0001911623
Frazier Life Sciences XII, L.P. 0.1% 54,163 0 54,163 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. 0002052255
FHMLS XII, L.P. 0.1% 54,163 0 54,163 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. 0002052246
FHMLS XII, L.L.C. 0.1% 54,163 0 54,163 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C. 0002052177
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .